The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors

Seminars in Oncology

Volumn 36, Issue SUPPL. 2, 2009, Pages

  Soffietti, Riccardo ^a   Akerley, Wallace ^b   Jensen, Randy L ^c   Bischoff, Joachim ^d   Regierer, Anne Constanze ^e  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; HYDROCORTISONE; LAPATINIB; METHOTREXATE; PACLITAXEL; PLACEBO; THIOTEPA; TRASTUZUMAB;

ADD ON THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID; CLINICAL TRIAL; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INJECTIONS, SPINAL; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; SURVIVAL ANALYSIS;

EID: 67849129120     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.05.007     Document Type: Article

References (95)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., and Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 (2004) 2865-2872
3. Gleissner G., and Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 5 (2006) 443-452
4. Balm M., and Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 53 (1996) 626-632
5. Bruno M.K., and Raizer J. Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). Cancer Treat Res 125 (2005) 31-52
6. Taillibert S., Laigle-Donadey F., Chodkiewicz C., Sanson M., Hoang-Xuan K., and Delattre J.Y. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75 (2005) 85-99
7. Olson M.E., Chernik N.L., and Posner J.B. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30 (1974) 122-137
8. Wasserstrom W.R., Glass J.P., and Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49 (1982) 759-772
9. Norris L.K., Grossman S.A., and Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol 32 (1997) 215-223
10. Siomin V.E., Vogelbaum M.A., Kanner A.A., Lee S.Y., Suh J.H., and Barnett G.H. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol 67 (2004) 115-121
11. Suki D., Abouassi H., Patel A.J., Sawaya R., Weinberg J.S., and Groves M.D. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 108 (2008) 248-257
12. van der Ree T.C., Dippel D.W., Avezaat C.J., Sillevis Smitt P.A., Vecht C.J., and van den Bent M.J. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psych 66 (1999) 225-227
13. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
14. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 (2004) 639-643
15. Seute T., Leffers P., ten Velde G.P., and Twijnstra A. Leptomeningeal metastases from small cell lung carcinoma. Cancer 104 (2005) 1700-1705
16. Omuro A.M., Kris M.G., Miller V.A., Franceschi E., Shah N., Milton D.T., and Abrey L.E. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103 (2005) 2344-2348
17. Patel R.R., and Mehta M.P. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13 (2007) 1675-1683
18. Andrews D.W., Scott C.B., Sperduto P.W., Flanders A.E., Gaspar L.E., Schell M.C., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (2004) 1665-1672
19. Soffietti R., Ruda R., and Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 20 (2008) 676-684
20. Jayson G.C., Howell A., Harris M., Morgenstern G., Chang J., and Ryder W.D. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 74 (1994) 3135-3141
21. Glantz M.J., Cole B.F., Recht L., Akerley W., Mills P., Saris S., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 16 (1998) 1561-1567
22. Chamberlain M.C. Neoplastic meningitis. Neurologist 12 (2006) 179-187
23. Yap H.Y., Yap B.S., Rasmussen S., Levens M.E., Hortobagyi G.N., and Blumenschein G.R. Treatment for meningeal carcinomatosis in breast cancer. Cancer 50 (1982) 219-222
24. Ongerboer de Visser B.W., Somers R., Nooyen W.H., van Heerde P., Hart A.A., and McVie J.G. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33 (1983) 1565-1572
25. Hitchins R.N., Bell D.R., Woods R.L., and Levi J.A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5 (1987) 1655-1662
26. Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., Trump D.L., Moynihan T., and Ettinger D.S. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11 (1993) 561-569
27. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 (1999) 3394-3402
28. Jaeckle K.A., Batchelor T., O'Day S.J., Phuphanich S., New P., Lesser G., et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57 (2002) 231-239
29. Kim D.Y., Lee K.W., Yun T., Park S.R., Jung J.Y., Kim D.W., et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33 (2003) 608-612
30. Boogerd W., van den Bent M.J., Koehler P.J., Heimans J.J., van der Sande J.J., Aaronson N.K., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40 (2004) 2726-2733
31. Bokstein F., Lossos A., and Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82 (1998) 1756-1763
32. Orlando L., Curigliano G., Colleoni M., Fazio N., Nole F., Martinelli G., et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 22 (2002) 3057-3059
33. Gavrilovic I.T., and Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 75 (2005) 5-14
34. Patanaphan V., Salazar O.M., and Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 81 (1988) 1109-1112
35. Tsukada Y., Fouad A., Pickren J.W., and Lane W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52 (1983) 2349-2354
36. Kesari S., and Batchelor T.T. Leptomeningeal metastases. Neurol Clin 21 (2003) 25-66
37. Jaeckle K.A., Phuphanich S., Bent M.J., Aiken R., Batchelor T., Campbell T., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84 (2001) 157-163
38. Wang M.L., Yung W.K., Royce M.E., Schomer D.F., and Theriault R.L. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24 (2001) 421-424
39. Fabi A., Vidiri A., Ferretti G., Felici A., Papaldo P., Carlini P., et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow?. Cancer Invest 24 (2006) 466-468
40. Tham Y.L., Hinckley L., Teh B.S., and Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7 (2006) 164-166
41. Giglio P., Tremont-Lukats I.W., and Groves M.D. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 65 (2003) 167-172
42. Rogers L.R., Remer S.E., and Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neurooncology 6 (2004) 63-64
43. Capecitabine [package insert] (2006), Roche Laboratories Inc, Nutley, NJ
44. Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
45. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997) 745-751
46. Slimane K., Andre F., Delaloge S., Dunant A., Perez A., Grenier J., et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15 (2004) 1640-1644
47. Gabos Z., Sinha R., Hanson J., Chauhan N., Hugh J., Mackey J.R., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24 (2006) 5658-5663
48. Souglakos J., Vamvakas L., Apostolaki S., Perraki M., Saridaki Z., Kazakou I., et al. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res 8 (2006) R36
49. Tham Y.L., Sexton K., Kramer R., Hilsenbeck S., and Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107 (2006) 696-704
50. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30 (2006) 1097-1104
51. Carey L.A., Ewend M.G., Metzger R., Sawyer L., Dees E.C., Sartor C.I., et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 88 (2004) 273-280
52. Evans A.J., James J.J., Cornford E.J., Chan S.Y., Burrell H.C., Pinder S.E., et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 16 (2004) 345-349
53. Gonzalez-Angulo A.M., Cristofanilli M., Strom E.A., Buzdar A.U., Kau S.W., Broglio K.R., et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101 (2004) 1760-1766
54. Ryberg M., Nielsen D., Osterlind K., Andersen P.K., Skovsgaard T., and Dombernowsky P. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 91 (2005) 217-225
55. Burstein H.J., Lieberman G., Slamon D.J., Winer E.P., and Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16 (2005) 1772-1777
56. Luck A.A., Evans A.J., Green A.R., Rakha E.A., Paish C., and Ellis I.O. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) 20 (2008) 40-45
57. Nam B.H., Kim S.Y., Han H.S., Kwon Y., Lee K.S., Kim T.H., and Ro J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10 (2008) R20
58. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 (1996) 737-744
59. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
60. Lower E.E., Drosick D.R., Blau R., Brennan L., Danneman W., and Hawley D.K. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4 (2003) 114-119
61. Van Pelt A.E., Mohsin S., Elledge R.M., Hilsenbeck S.G., Gutierrez M.C., Lucci Jr. A., et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4 (2003) 348-353
62. Lai R., Dang C.T., Malkin M.G., and Abrey L.E. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101 (2004) 810-816
63. Shmueli E., Wigler N., and Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40 (2004) 379-382
64. Stemmler H.J., Kahlert S., Siekiera W., Untch M., Heinrich B., and Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15 (2006) 219-225
65. Yau T., Swanton C., Chua S., Sue A., Walsh G., Rostom A., et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45 (2006) 196-201
66. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
67. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112 (2008) 533-543
68. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Ewend M., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26 (2008) 1993-1999
69. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
70. Mamon H.J., Yeap B.Y., Janne P.A., Reblando J., Shrager S., Jaklitsch M.T., et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23 (2005) 1530-1537
71. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
72. Law A., Karp D.D., Dipetrillo T., and Daly B.T. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer 92 (2001) 160-164
73. Robnett T.J., Machtay M., Stevenson J.P., Algazy K.M., and Hahn S.M. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 19 (2001) 1344-1349
74. Ceresoli G.L., Reni M., Chiesa G., Carretta A., Schipani S., Passoni P., et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 95 (2002) 605-612
75. Machtay M., Lee J.H., Stevenson J.P., Shrager J.B., Algazy K.M., Treat J., and Kaiser L.R. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg 127 (2004) 108-113
76. Gaspar L.E., Chansky K., Albain K.S., Vallieres E., Rusch V., Crowley J.J., et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 23 (2005) 2955-2961
77. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
78. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
79. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
80. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
81. Hotta K., Kiura K., Ueoka H., Tabata M., Fujiwara K., Kozuki T., et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46 (2004) 255-261
82. Shimato S., Mitsudomi T., Kosaka T., Yatabe Y., Wakabayashi T., Mizuno M., et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neurooncol 8 (2006) 137-144
83. Berghmans T., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3 (2008) 6-12
84. Hochstenbag M.M., Twijnstra A., Wilmink J.T., Wouters E.F., and ten Velde G.P. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 48 (2000) 243-248
85. Seute T., Leffers P., ten Velde G.P., and Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 100 (2004) 801-806
86. Nugent J.L., Bunn Jr. P.A., Matthews M.J., Ihde D.C., Cohen M.H., Gazdar A., et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 44 (1979) 1885-1893
87. Rosen S.T., Aisner J., Makuch R.W., Matthews M.J., Ihde D.C., Whitacre M., et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine 61 (1982) 45-53
88. Aisner J., Ostrow S., Govindan S., and Wiernik P.H. Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Med Pediatr Oncol 9 (1981) 47-59
89. Aroney R.S., Dalley D.N., Chan W.K., Bell D.R., and Levi J.A. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 71 (1981) 26-32
90. Auperin A., Arriagada R., Pignon J.P., Le Pechoux C., Gregor A., Stephens R.J., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 (1999) 476-484
91. Lee J.J., Bekele B.N., Zhou X., Cantor S.B., Komaki R., and Lee J.S. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol 24 (2006) 3597-3603
92. Slotman B., Faivre-Finn C., Kramer G., Rankin E., Snee M., Hatton M., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (2007) 664-672
93. Mirimanoff R.O., and Choi N.C. Intradural spinal metastases in patients with posterior fossa brain metastases from various primary cancers. Oncology 44 (1987) 232-236
94. Phillips P.C., Than T.T., Cork L.C., Hilton J., Carson B.S., Colvin O.M., and Grochow L.B. Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 52 (1992) 6168-6174
95. Ratilal R., Costa J., and Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane Database Syst Rev (Online) 3 (2006) CD005365